FDA Approves New Antiviral for Refractory HSV in Immunocompromised Patients

The FDA has approved HOVILPRI (pritelivir) 100 mg tablets for treating mucocutaneous herpes simplex virus lesions in immunocompromised adults when standard antivirals are ineffective. This marks the first FDA-approved HSV therapy with a novel mechanism in nearly 30 years, offering a new treatment option for a vulnerable patient population. The approval is based on positive Phase 3 trial results.